Table 1.
Clinical characteristics of the SAFHS included in this study (n = 1, 383).
| Characteristic | N ∗ | Description∗∗ |
|---|---|---|
| Age at enrolment (y) | 1,383 | 39.17 (0.45) |
| Females | 1,383 | 822 (59.43) |
| Waist (cm) | 1,371 | 94.71 (0.47) |
| Central obesity (waist circumference ≥102 cm for males and ≥88 cm for females) | 1,371 | 641 (46.75) |
| Body mass index (BMI, Kg/m2) | 1,372 | 29.24 (0.18) |
| Obesity (BMI ≥ 30 Kg/m2) | 1,372 | 531 (38.70) |
| Systolic blood pressure (SBP, mmHg) | 1,372 | 120.38 (0.51) |
| Diastolic blood pressure (DBP, mmHg) | 1,372 | 70.67 (0.28) |
| Hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) | 1,372 | 247 (18.00) |
| Type 2 diabetes | 169 (20.58) | |
| Prevalent T2D at baseline visit | 1,383 | 208 (15.04) |
| Incident T2D detected during follow-up† | 913 | 149 (16.32) |
| Ever T2D | 1,383 | 357 (25.81) |
| Fasting glucose (mmol/L)† | 1,171 | 4.82 (0.02) |
| 2-hour postchallenge glucose (mmol/L)† | 1,143 | 5.61 (0.05) |
| Fasting insulin† | 1,153 | 14.11 (0.46) |
| 2-hour postchallenge insulin† | 1,115 | 76.86 (2.19) |
| HOMA-IR† | 1,153 | 3.16 (0.13) |
| HOMA-β † | 1,153 | 19.38 (1.67) |
| Total serum cholesterol (mg/dL) | 1,379 | 189.27 (1.06) |
| Serum triglycerides (mg/dL) | 1,379 | 150.10 (3.48) |
| HDL cholesterol (mg/dL) | 1,378 | 50.14 (0.35) |
| Medication use at baseline | ||
| Antihypertensive medications | 1,376 | 132 (9.59) |
| Lipid lowering medications | 1,376 | 25 (1.82) |
∗Number of individuals for whom data was available.
∗∗Numbers indicate mean (SE) for continuous variables and n (%) for categorical variables.
†These variables are reported only for individuals who did not have T2D at baseline.